Hypoaldosteronism pathophysiology

Jump to navigation Jump to search

Hypoaldosteronism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hypoaldosteronism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypoaldosteronism pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hypoaldosteronism pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypoaldosteronism pathophysiology

CDC on Hypoaldosteronism pathophysiology

Hypoaldosteronism pathophysiology in the news

Blogs on Hypoaldosteronism pathophysiology

Directions to Hospitals Treating Hypoaldosteronism

Risk calculators and risk factors for Hypoaldosteronism pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

The exact pathogenesis of [disease name] is not fully understood.

OR

It is thought that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].

OR

[Pathogen name] is usually transmitted via the [transmission route] route to the human host.

OR

Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell.

OR


[Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells].

OR

The progression to [disease name] usually involves the [molecular pathway].

OR

The pathophysiology of [disease/malignancy] depends on the histological subtype.

Pathophysiology

Hypoaldosteronism is defined as decreased levels of the hormone aldosterone (Normal range: 1-21 ng/dL). Hypoaldosteronism from decreased aldosterone synthesis can be due to :

  • Adrenal Insufficiency: Primary or secondary
  • Enzyme deficiency: Aldosterone synthase, 21 hydroxylase, and 11B hydroxylase
  • Renal disorders: Chronic renal failure and diabetic nephropathy
  • Drugs inhibiting aldosterone effect: NSAID, spironolactone, and triamterene


Pathophysiology

Pathogenesis

  • The exact pathogenesis of [disease name] is not fully understood.

OR

  • It is thought that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].
  • [Pathogen name] is usually transmitted via the [transmission route] route to the human host.
  • Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell.
  • [Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells].
  • The progression to [disease name] usually involves the [molecular pathway].
  • The pathophysiology of [disease/malignancy] depends on the histological subtype.

Genetics

  • Hypoaldosteronism is transmitted in autosomal recessive pattern.
  • Gene involved in the pathogenesis of hypoaldosteronism include mutation in CYP11B2 gene, which is located on chromosome 8q24.
  • The CYP11B2 gene encodes for the enzyme aldosterone synthase (previously known as corticosterone methyloxidase).
  • Aldosterone synthase catalyses the conversion of: 11 Deoxycorticosterone to aldosterone
 
 
 
11 Deoxycorticosterone
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corticosterone
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18 Hydroxycorticosterone
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aldosterone
 
 
 


  • Mutations in CYP11B2 can lead to:
    • Type 1 aldosterone synthase deficiency: Patients has normal to decreased levels of 18-hydroxycorticosterone and undetectable levels of aldosterone.
    • Type 2 aldosterone synthase deficiency: Patients has increased levels of 18-hydroxycorticosterone and normal to decreased levels of aldosterone.
  • Aldosterone synthase is a member of the cytochrome P450 family of enzymes.

Associated Conditions

Gross Pathology

  • On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Microscopic Pathology

  • On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

References

Template:WH Template:WS